Developer docs
API playgroundTry for free, no card

Search company profiles

OneSource

Full company profile

uuid00026k8

Namestring
OneSource
Legal namestring
OneSource Specialty Pharma Limited
Company typeenum
Public
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBangalore, India
HQ citystring
Bangalore
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO services, drug-device combinations, complex sterile injectables, biologics manufacturing, soft gelatin capsules
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services (CDMO)
TypeManaged Services
Description

End-to-end CDMO services spanning early-stage development, clinical supply, and commercial manufacturing. Revenue generated through development fees, manufacturing service fees, and long-term supply agreements. The company signs Master Service Agreements (MSAs) with customers; signed 9 new MSAs in Q2FY26. Revenue model is transitioning toward IP-led base business sales and Take-and-Pay contracts linked to commercial supply of products like semaglutide.

onesourcecdmo.com
2IP-Led Base Business
TypeLicensing Royalties
Description

Revenue from intellectual property-led base business including commercialized products manufactured for partners. Includes 19 commercialized drug products in the United States and multiple approved ANDAs across sterile injectables, biologics, and drug-device combinations.

indianexpress.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

OneSource is a specialty pharma Contract Development and Manufacturing Organization (CDMO) offering end-to-end services from early-stage development through commercial manufacturing across four core platforms: drug-device combinations, complex sterile injectables, biologics, and soft gelatin capsules. The company manufactures pharmaceutical products under Master Service Agreements and supply contracts for global pharmaceutical and biotech clients, operating from five US FDA-approved facilities in Bengaluru, India. Strategic offerings include peptide GLP-1 manufacturing (semaglutide), proprietary HILOPRO® high-concentration formulation platform, and SEDDS/SMEDDS/SNEDDS lipid softgel technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 232.4% CAGR in consolidated revenue between FY23 and FY26 — fastest among Indian pharma companies analyzed
+4 more records
Product overview1 text field

OneSource Specialty Pharma is a multimodal specialty pharma Contract Development and Manufacturing Organization (CDMO) offering end-to-end CDMO services across four core technology platforms: drug-device combinations (prefilled syringes, pen injectors, autoinjectors), complex injectables (sterile liquids, lyophilized vials, dry powder), biologics (microbial/mammalian cell line, cell & gene therapy, RNA), and soft gelatin capsules (2.4 billion capsules/year capacity). The company operates five USFDA-approved facilities in Bengaluru, India, providing integrated services from early-stage development through commercial manufacturing. Strategic proprietary platforms include the HILOPRO® high-concentration subcutaneous formulation platform, self-emulsifying softgel technology (SEDDS/SMEDDS/SNEDDS), and a GLP-1 peptide development platform. The company was demerged from Strides Pharma in 2024 and listed separately in January 2025.

Product and service5 records
1Drug-Device Combinations Manufacturing
CategoryDrug-Device Combinations
Description

End-to-end development and manufacturing of specialized drug-device combination products for pharmaceutical and biotech clients, including prefilled syringes, dial-and-push variable and fixed-dose pen injectors, pull-push fixed-dose pens, and autoinjectors. Supported by 20+ automatic and semi-automatic flexible assembly stations across multiple device formats.

2Complex Injectables Manufacturing
CategorySterile Injectables
Description

Development and manufacturing of complex injectable drug products in multiple dosage forms including sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections for global pharmaceutical clients. Backed by 35 approved ANDAs and 19 commercialized drug products in the United States.

3Biologics Manufacturing
CategoryBiologics CDMO
Description

Integrated biologics development and manufacturing services covering microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products, with 550,000 ft² of dedicated process development and drug substance manufacturing space at the Bengaluru campus.

4Soft Gelatin Capsules (Softgels)
CategorySoft Gelatin Capsules
Description

Development and manufacturing of soft gelatin capsule technologies with 2.4 billion capsules per year capacity, including traditional softgels, enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories across multiple shapes and sizes.

5Generic Semaglutide CDMO Manufacturing
CategoryGeneric GLP-1 Manufacturing
Description

End-to-end contract manufacturing of generic semaglutide injection (generic Ozempic GLP-1 therapy) for global pharmaceutical partners including Dr. Reddy's, Apotex/Orbicular, and Hikma Pharmaceuticals across Canada, US, Saudi Arabia, and MENA markets.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeOthersAnnounced on2026-05-25
Description

OneSource's board decided not to proceed with the proposed transaction with Brooks Steriscience, stating it was not in the best interest of stakeholders. Brooks Steriscience echoed a similar stance, confirming termination of the proposed transaction. The deal was part of a Composite Scheme of Arrangement that also involved Steriscience Pte Limited and Strides Pharma Services Private Limited. No reasons were provided for the decision.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-04
Description

Orbicular Pharmaceutical Technologies led product development and technical program for generic Ozempic (semaglutide injection), with OneSource providing end-to-end manufacturing from its US FDA-approved Bengaluru facility. The partnership secured tentative US FDA approval (April 2026) and Health Canada approval (May 2026), making it one of the first generic entrants in both markets. Orbicular used its Canadian front-end partner for the Apotex approval and a US-based ANDA holder for the US market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

OneSource serves as CDMO (Contract Development and Manufacturing Organization) partner for Dr. Reddy's generic semaglutide injection (generic Ozempic). OneSource manufactures the finished product at its US FDA-approved Bengaluru facility while Dr. Reddy's produces the active pharmaceutical ingredient (API) in-house. Health Canada granted approval in April 2026, making it the first generic semaglutide approval in Canada (a G7 market). The Canadian market is estimated at $1.5-1.8 billion. A second approval followed for Apotex, also manufactured by OneSource.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-11
Description

Exclusive partnership for commercializing generic Ozempic (semaglutide) in Saudi Arabia and the broader Middle East and North Africa (MENA) region. OneSource manufactures and supplies the drug from its Bengaluru facility while Hikma Pharmaceuticals (largest pharmaceutical company in MENA by sales) handles commercialization through its established commercial network and institutional relationships. SFDA approval secured in February 2026.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-06-11
Description

OneSource and Xbrane Biopharma announced a biosimilars manufacturing partnership for global markets in June 2025. OneSource will provide manufacturing capabilities for Xbrane's biosimilar programs targeting global commercialization.

Strategic tierStrategicTypeTechnology or Integration
Description

OneSource accesses the patented HILOPRO high-concentration formulation platform through strategic partnership with Bhami Research Lab. The platform is validated across six commercial molecules and enables subcutaneous delivery of high-dose biologics by solving viscosity and concentration challenges.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Syngene International
TypeDirect peer
Description

Indian-listed CRO/CDMO with biologics manufacturing and integrated discovery-to-commercial services for global pharma. Directly comparable in business model and customer base (innovator biopharma), though Syngene leans more discovery/research-heavy.

TypeDirect peer
Description

Indian CDMO with capabilities in intermediates, APIs, and formulations including complex injectables. Comparable as a contract-focused Indian pharma services business serving global innovators and generics players.

TypeBroad incumbent
Description

South Korean biologics CDMO with very large single-site capacity. A direct competitor for biologics manufacturing and subcutaneous biologic programs where OneSource's HILOPRO platform plays.

TypeDirect peer
Description

Indian pharma company with CDMO operations in sterile injectables, APIs, and radiopharmaceuticals. Comparable in modality mix (sterile injectables, complex generics) and in serving regulated markets, with FDA-approved facilities.

TypeBroad incumbent
Description

Global biologics CDMO with end-to-end capabilities across mAbs, bispecifics, and ADCs. Comparable in biologics DS/DP integration, but at materially larger scale and with a broader innovator-biopharma customer base.

TypeBroad incumbent
Description

Global leader in biologics and small-molecule CDMO with end-to-end drug substance and drug product services. OneSource competes for the same complex injectables and biologics programs, but Lonza is a far larger incumbent with deeper innovator-biopharma relationships.

TypeBroad incumbent
Description

Global CDMO with leading positions in softgel, drug-device combinations, and biologics fill-finish. A direct competitor in softgels and drug-device combinations, now owned by Novo Holdings (relevant given OneSource's semaglutide exposure).

TypeDirect peer
Description

Indian-headquartered CDMO offering sterile injectables, complex APIs, and drug-device combination manufacturing for global pharma. Most direct Indian peer for OneSource's sterile injectables and complex generics work, with overlapping customers and similar regulatory profile.

TypeRegional player
Description

Indian-headquartered generics manufacturer with significant injectables, biosimilars, and API operations. Comparable in sterile injectables and complex generics manufacturing, with a similar India-based, FDA-inspected footprint; primarily serves its own generic brands plus third-party CDMO.

TypeDirect peer
Description

Indian API and intermediates manufacturer with growing formulation and CDMO exposure. Comparable in regulated-market supply and scale, with similar FDA-inspected infrastructure and global pharma customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OneSource

Pharmaceutical CDMO Servicesonesourcecdmo.com

OneSource firmographics

Firmographics
Name
OneSource
Legal name
OneSource Specialty Pharma Limited
Website
https://onesourcecdmo.com
Company type
Public
Founded year
2024
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

OneSource industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical CDMO services
  • Drug-device combinations
  • Complex sterile injectables
  • Biologics manufacturing
  • Soft gelatin capsules

Where OneSource is headquartered

Location

Headquarters

HQ city
Bangalore
HQ country
India
HQ region
Asia

Offices5 records

Markets served

OneSource business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing Services (CDMO): End-to-end CDMO services spanning early-stage development, clinical supply, and commercial manufacturing. Revenue generated through development fees, manufacturing service fees, and long-term supply agreements. The company signs Master Service Agreements (MSAs) with customers; signed 9 new MSAs in Q2FY26. Revenue model is transitioning toward IP-led base business sales and Take-and-Pay contracts linked to commercial supply of products like semaglutide.
  2. IP-Led Base Business: Revenue from intellectual property-led base business including commercialized products manufactured for partners. Includes 19 commercialized drug products in the United States and multiple approved ANDAs across sterile injectables, biologics, and drug-device combinations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

OneSource product offering

Product offering

Core offering

OneSource is a specialty pharma Contract Development and Manufacturing Organization (CDMO) offering end-to-end services from early-stage development through commercial manufacturing across four core platforms: drug-device combinations, complex sterile injectables, biologics, and soft gelatin capsules. The company manufactures pharmaceutical products under Master Service Agreements and supply contracts for global pharmaceutical and biotech clients, operating from five US FDA-approved facilities in Bengaluru, India. Strategic offerings include peptide GLP-1 manufacturing (semaglutide), proprietary HILOPRO® high-concentration formulation platform, and SEDDS/SMEDDS/SNEDDS lipid softgel technology.

Product overview

OneSource Specialty Pharma is a multimodal specialty pharma Contract Development and Manufacturing Organization (CDMO) offering end-to-end CDMO services across four core technology platforms: drug-device combinations (prefilled syringes, pen injectors, autoinjectors), complex injectables (sterile liquids, lyophilized vials, dry powder), biologics (microbial/mammalian cell line, cell & gene therapy, RNA), and soft gelatin capsules (2.4 billion capsules/year capacity). The company operates five USFDA-approved facilities in Bengaluru, India, providing integrated services from early-stage development through commercial manufacturing. Strategic proprietary platforms include the HILOPRO® high-concentration subcutaneous formulation platform, self-emulsifying softgel technology (SEDDS/SMEDDS/SNEDDS), and a GLP-1 peptide development platform. The company was demerged from Strides Pharma in 2024 and listed separately in January 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug-Device Combinations Manufacturing End-to-end development and manufacturing of specialized drug-device combination products for pharmaceutical and biotech clients, including prefilled syringes, dial-and-push variable and fixed-dose pen injectors, pull-push fixed-dose pens, and autoinjectors. Supported by 20+ automatic and semi-automatic flexible assembly stations across multiple device formats.
  • Complex Injectables Manufacturing Development and manufacturing of complex injectable drug products in multiple dosage forms including sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections for global pharmaceutical clients. Backed by 35 approved ANDAs and 19 commercialized drug products in the United States.
  • Biologics Manufacturing Integrated biologics development and manufacturing services covering microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products, with 550,000 ft² of dedicated process development and drug substance manufacturing space at the Bengaluru campus.
  • Soft Gelatin Capsules (Softgels) Development and manufacturing of soft gelatin capsule technologies with 2.4 billion capsules per year capacity, including traditional softgels, enteric coated capsules, vegan alternatives, chewable formats, vaginal pessaries, liposomal capsules, applicaps, and suppositories across multiple shapes and sizes.
  • Generic Semaglutide CDMO Manufacturing End-to-end contract manufacturing of generic semaglutide injection (generic Ozempic GLP-1 therapy) for global pharmaceutical partners including Dr. Reddy's, Apotex/Orbicular, and Hikma Pharmaceuticals across Canada, US, Saudi Arabia, and MENA markets.

Quantifiable outcome

  • 232.4% CAGR in consolidated revenue between FY23 and FY26 — fastest among Indian pharma companies analyzed
  • +4 more outcomes

Companies that use OneSource

Customer profile

Named customers5 records

Segments1 record

Ideal customer profiles1 record

OneSource technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

OneSource partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor, core and strategic.

  • Brooks SteriscienceminorOthers · 25 May 2026OneSource's board decided not to proceed with the proposed transaction with Brooks Steriscience, stating it was not in the best interest of stakeholders. Brooks Steriscience echoed a similar stance, confirming termination of the proposed transaction. The deal was part of a Composite Scheme of Arrangement that also involved Steriscience Pte Limited and Strides Pharma Services Private Limited. No reasons were provided for the decision.
  • Orbicular Pharmaceutical TechnologiescoreStrategic or Co-development Partner · 4 May 2026Orbicular Pharmaceutical Technologies led product development and technical program for generic Ozempic (semaglutide injection), with OneSource providing end-to-end manufacturing from its US FDA-approved Bengaluru facility. The partnership secured tentative US FDA approval (April 2026) and Health Canada approval (May 2026), making it one of the first generic entrants in both markets. Orbicular used its Canadian front-end partner for the Apotex approval and a US-based ANDA holder for the US market.
  • Dr. Reddy's LaboratoriescoreStrategic or Co-development Partner · 29 April 2026OneSource serves as CDMO (Contract Development and Manufacturing Organization) partner for Dr. Reddy's generic semaglutide injection (generic Ozempic). OneSource manufactures the finished product at its US FDA-approved Bengaluru facility while Dr. Reddy's produces the active pharmaceutical ingredient (API) in-house. Health Canada granted approval in April 2026, making it the first generic semaglutide approval in Canada (a G7 market). The Canadian market is estimated at $1.5-1.8 billion. A second approval followed for Apotex, also manufactured by OneSource.
  • Hikma PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 11 February 2026Exclusive partnership for commercializing generic Ozempic (semaglutide) in Saudi Arabia and the broader Middle East and North Africa (MENA) region. OneSource manufactures and supplies the drug from its Bengaluru facility while Hikma Pharmaceuticals (largest pharmaceutical company in MENA by sales) handles commercialization through its established commercial network and institutional relationships. SFDA approval secured in February 2026.
  • Xbrane BiopharmastrategicStrategic or Co-development Partner · 11 June 2025OneSource and Xbrane Biopharma announced a biosimilars manufacturing partnership for global markets in June 2025. OneSource will provide manufacturing capabilities for Xbrane's biosimilar programs targeting global commercialization.
  • Bhami Research LabstrategicTechnology or IntegrationOneSource accesses the patented HILOPRO high-concentration formulation platform through strategic partnership with Bhami Research Lab. The platform is validated across six commercial molecules and enables subcutaneous delivery of high-dose biologics by solving viscosity and concentration challenges.

Scale indicators15 records

Recent moves9 records

Expansion highlights5 records

OneSource competitors and assessment

Company assessment

Direct peers

  • Syngene International: Indian-listed CRO/CDMO with biologics manufacturing and integrated discovery-to-commercial services for global pharma. Directly comparable in business model and customer base (innovator biopharma), though Syngene leans more discovery/research-heavy.
  • Suven Pharmaceuticals: Indian CDMO with capabilities in intermediates, APIs, and formulations including complex injectables. Comparable as a contract-focused Indian pharma services business serving global innovators and generics players.
  • Jubilant Pharmova: Indian pharma company with CDMO operations in sterile injectables, APIs, and radiopharmaceuticals. Comparable in modality mix (sterile injectables, complex generics) and in serving regulated markets, with FDA-approved facilities.
  • Piramal Pharma Solutions: Indian-headquartered CDMO offering sterile injectables, complex APIs, and drug-device combination manufacturing for global pharma. Most direct Indian peer for OneSource's sterile injectables and complex generics work, with overlapping customers and similar regulatory profile.
  • Divis Laboratories: Indian API and intermediates manufacturer with growing formulation and CDMO exposure. Comparable in regulated-market supply and scale, with similar FDA-inspected infrastructure and global pharma customer base.

Broad incumbents

  • Samsung Biologics: South Korean biologics CDMO with very large single-site capacity. A direct competitor for biologics manufacturing and subcutaneous biologic programs where OneSource's HILOPRO platform plays.
  • WuXi Biologics: Global biologics CDMO with end-to-end capabilities across mAbs, bispecifics, and ADCs. Comparable in biologics DS/DP integration, but at materially larger scale and with a broader innovator-biopharma customer base.
  • Lonza Group: Global leader in biologics and small-molecule CDMO with end-to-end drug substance and drug product services. OneSource competes for the same complex injectables and biologics programs, but Lonza is a far larger incumbent with deeper innovator-biopharma relationships.
  • Catalent (Novo Holdings): Global CDMO with leading positions in softgel, drug-device combinations, and biologics fill-finish. A direct competitor in softgels and drug-device combinations, now owned by Novo Holdings (relevant given OneSource's semaglutide exposure).

Regional players

  • Aurobindo Pharma: Indian-headquartered generics manufacturer with significant injectables, biosimilars, and API operations. Comparable in sterile injectables and complex generics manufacturing, with a similar India-based, FDA-inspected footprint; primarily serves its own generic brands plus third-party CDMO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

OneSource social profiles

Digital presence

OneSource compliance and trust

Trust signal

Compliance8 records

OneSource financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OneSource leadership team

Management profile

Number of profiles

Profiles13 records

OneSource subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

OneSource funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OneSource M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OneSource

What does OneSource do?

OneSource is a specialty pharma Contract Development and Manufacturing Organization (CDMO) offering end-to-end services from early-stage development through commercial manufacturing across four core platforms: drug-device combinations, complex sterile injectables, biologics, and soft gelatin capsules. The company manufactures pharmaceutical products under Master Service Agreements and supply contracts for global pharmaceutical and biotech clients, operating from five US FDA-approved facilities in Bengaluru, India. Strategic offerings include peptide GLP-1 manufacturing (semaglutide), proprietary HILOPRO® high-concentration formulation platform, and SEDDS/SMEDDS/SNEDDS lipid softgel technology.

Is OneSource a public or private company?

OneSource is a public company. It is classified as public and is currently operating.

When was OneSource founded?

OneSource was founded in 2024. It employs 501 to 1,000 people.

Where is OneSource based?

OneSource is headquartered in Bangalore, India, in the Asia region.

How does OneSource make money?

Two revenue lines are on record. Contract Development and Manufacturing Services (CDMO) is the primary driver. The others are IP-Led Base Business.

Who are OneSource's main competitors?

Direct peers on record are Syngene International, Suven Pharmaceuticals, Jubilant Pharmova, Piramal Pharma Solutions and Divis Laboratories. Broad incumbents are Samsung Biologics, WuXi Biologics, Lonza Group and Catalent (Novo Holdings). Aurobindo Pharma is listed as a regional player.

Does OneSource have an API?

No public API is recorded for OneSource.

What industry is OneSource in?

OneSource's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StWe Might See A Profit From OneSource Specialty Pharma Limited (NSE:ONESOURCE) SoonAnalysts expect OneSource Specialty Pharma to breakeven within 12 months, posting a final loss in 2026 and a profit of ₹4.6b in 2027. The company's average annual growth rate is expected to be 70%, with debt at 25% of equity.ArgaamAvalon’s Generic Mounjaro Is Not Yet Saudi-MadeAvalon Pharma licensed a generic tirzepatide (Mounjaro) to OneSource Specialty Pharma, with no launch date. The deal could generate at least SAR800 million in five years, but Saudi production is not yet confirmed. Launch depends on patent expirations and manufacturing transfer.CNBCTV18OneSource Specialty sees Canada semaglutide supplies driving second half FY27 growth - CNBC TV18OneSource Specialty Pharma expects semaglutide supplies to Dr Reddy's and other customers in Canada to drive second-half FY27 growth, with manufacturing starting in Q3FY27. The company targets $400 million in revenue by FY28, with biologics and injectables also contributing.TradingViewOneSource Specialty Pharma shares jump 14% after Q2 results; recover 50% from recent lowsOneSource Specialty Pharma shares rose nearly 14% on October 27 after reporting Q2 revenue of Rs.516.2 crore, up 37% year-on-year. EBITDA climbed 53% to Rs.163.3 crore, and adjusted PAT surged 1,372% to Rs.93.7 crore. The company expects DDC capacity to triple by FY28.Business News TodayOneSource Specialty Pharma’s Q2 profit more than doubles on new capacity, volume growth- Moneycontrol.comOneSource Specialty Pharma reported a 109% year-on-year jump in adjusted net profit to Rs 93.7 crore in Q2, driven by new drug-device combination capacity and product launches. Revenue rose 37% to Rs 516 crore, and the company reaffirmed its FY28 revenue and EBITDA targets.Business StandardDr Reddy's launches new generic Ozempic brands amid Obeda supply disruptionDr Reddy's launched generic Ozempic brands Obeda Pro and Obeda Plus after its original Obeda injection supply was halted in July due to an impurity. The new products are made by Hetero Labs, while Obeda was made by OneSource Specialty Pharma. Dr Reddy's may discontinue Obeda and focus on the new brands.ScanXOneSource Specialty Pharma appoints B S R & Co as statutory auditorsOneSource Specialty Pharma appointed B S R & Co LLP as statutory auditors for five years at its 19th AGM on September 23, 2026. The firm will serve until the 24th AGM, and shareholders also adopted FY26 financials and re-appointed Neeraj Sharma as director.ScanXOneSource Pharma adds RPT details to AGM notice for Sept 23 meetingOneSource Specialty Pharma issued an addendum to its 19th AGM notice for September 23, 2026, disclosing additional details on related party transactions with Strides Pharma Science Limited and its US subsidiary. The Audit Committee reviewed CEO and CFO certificates per industry standards, and the addendum was filed with BSE and NSE.ScanXOneSource Specialty Pharma files FY26 BRSR report with zero liquid dischargeOneSource Specialty Pharma filed its FY26 BRSR report on August 31, 2026, disclosing a standalone turnover of ₹14,204 million and net worth of ₹59,430.95 million. The company achieved zero liquid discharge, renewable energy consumption rose to 1,13,219 GJ, and permanent employee turnover fell to 23%.ScanXOneSource Specialty Pharma sets 19th AGM for September 23, 2026OneSource Specialty Pharma has scheduled its 19th Annual General Meeting for September 23, 2026, at 11:00 am IST via video conferencing or other audio-visual means, with voting through the NSDL platform. The company will send the FY25-26 annual report electronically to registered members. The notice does not disclose the resolutions to be tabled.